Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples